A Study of RSLV-132 in Females With Sjögren's Disease
Purpose
The goal of this clinical study is to learn if RSLV-132 improves the symptoms of SS in adults. It will also learn about the safety of RSLV-132. The main questions it aims to answer are: - Does RSLV-132 improve the cardinal symptoms of Sjogren's including fatigue, dryness and pain? - Does RSLV-132 improve the tiredness/fatigue caused by Sjogren's? - What are the blood levels of RSLV-132 over time? - What is the immune (antibody) response in the body to RSLV-132? - What is the safety profile of RSLV-132? Researchers will compare RSLV-132 to a placebo (a look-alike substance that contains no drug) to see if RSLV-132 improves the symptoms of pSS. Participants will: Take RSLV-132 or a placebo 13 times over 22 weeks Visit the clinic once every week for the first 2 weeks, then every 2 weeks until the end of treatment and then for a final time 4 weeks later (Day 211) for check-ups, tests and to answer questionnaires about their symptoms Record their symptoms every day on an electronic device
Condition
- Primary Sjögren Syndrome
Eligibility
- Eligible Ages
- Between 18 Years and 75 Years
- Eligible Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Providing written informed consent - Weight at least 45 kg - Meet the 2016 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Classification Criteria for pSS - Diagnosis in the last 30 years - Positive anti-Ro/SSA antibody test - Score of 5 or higher on the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) scale and the ESSPRI fatigue scale - Of non childbearing potential or of childbearing potential and using highly effective contraceptive measures
Exclusion Criteria
- Diagnosis of any active autoimmune disease other than pSS that could affect the efficacy assessments - Uncontrolled hypothyroidism or severe fibromyalgia - New medications or change in medications in the last 4 weeks for pSS symptoms - Receipt of other prohibited medications - Apheresis or blood donation - Allergic reaction to RSLV-132 or biologic therapy - Clinically significant infection in last 30 days - Participation in another clinical study - Malignancy in last 5 years - Positive test for HIV or hepatitis - Major surgery in last 30 days or anticipated surgery during the study - Pregnancy or breast feeding - Laboratory blood tests outside of specified ranges - Other medical conditions or medications that would make the participant unsuitable
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental RSLV-132 |
Intravenous infusions of 10 mg/kg RSLV-132 solution on Days 1, 8, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, and 155) for a total of 22 weeks of treatment |
|
|
Placebo Comparator Placebo |
Intravenous infusions of placebo solution on Days 1, 8, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, and 155) for a total of 22 weeks of treatment |
|
Recruiting Locations
Chula Vista 5336899, California 5332921 91910
Albuquerque 5454711, New Mexico 5481136 87106
Charlotte 4460243, North Carolina 4482348 28204
Charlotte 4460243, North Carolina 4482348 28208
Salisbury 4489985, North Carolina 4482348 28277
Duncansville 5187508, Pennsylvania 6254927 16635
More Details
- Status
- Recruiting
- Sponsor
- Resolve Therapeutics
Study Contact
PatientWing https://app.patientwing.com/campaign/clinicaltrials.gov(213) 459-2979
studies@patientwing.com